Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 589

Results For "IP"

11086 News Found

Shilpa Medicare directed to to pay damage to Celltrion
News | January 25, 2024

Shilpa Medicare directed to to pay damage to Celltrion

The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement


Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr
News | January 25, 2024

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023


Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
News | January 25, 2024

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023


BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO
People | January 25, 2024

BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO

An accomplished R&D leader and champion of the application of AI to drug discovery


ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
People | January 24, 2024

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom


Aster DM Healthcare gets shareholders nod to separate the GCC business
News | January 24, 2024

Aster DM Healthcare gets shareholders nod to separate the GCC business

The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years


Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
Clinical Trials | January 23, 2024

Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial


European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
Clinical Trials | January 23, 2024

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union


Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
News | January 23, 2024

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023